Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer

Title: Exelixis Provides Exciting Update on Phase 3 CONTACT-03 Trial for Advanced Kidney Cancer Treatment


The fight against advanced kidney cancer is receiving a significant boost as pharmaceutical company Exelixis provides a positive update on the Phase 3 CONTACT-03 trial. This trial evaluates the combination of cabozantinib, an Exelixis-developed TKI inhibitor, with atezolizumab, an immunotherapy drug, for patients with previously treated advanced kidney cancer. In this blog post, we will focus on the key points of Exelixis’ update and the potential impact of this promising treatment combination.

Key Points:

  1. Understanding Advanced Kidney Cancer:

Advanced or metastatic kidney cancer, also known as renal cell carcinoma, is a challenging condition with limited treatment options. As the disease progresses, patients face difficulties in finding effective therapies. Therefore, there is a critical need for breakthrough treatments to address the high unmet medical needs of this patient population.

  1. Introduction to Cabozantinib and Atezolizumab:

Cabozantinib is a tyrosine kinase inhibitor (TKI) developed by Exelixis that blocks multiple pathways involved in cancer growth. It has shown efficacy in treating various cancer types, including advanced kidney cancer. Atezolizumab, on the other hand, is an immune checkpoint inhibitor that works by enhancing the body’s immune response against cancer cells. By combining these two drugs, the hope is to leverage their complementary mechanisms of action for improved outcomes.

  1. Positive Update on the CONTACT-03 Trial:

Exelixis recently provided an update on the Phase 3 CONTACT-03 trial, evaluating the combination of cabozantinib and atezolizumab in patients with previously treated advanced kidney cancer. The trial met its primary endpoint, showing a statistically significant improvement in progression-free survival (PFS) compared to the standard of care, sunitinib. This positive outcome suggests the potential of the cabozantinib-atezolizumab combination to become a new treatment option for advanced kidney cancer patients.

  1. Implications for Patient Care:

The positive results from the CONTACT-03 trial hold significant implications for patients with previously treated advanced kidney cancer. The combination of cabozantinib and atezolizumab has demonstrated the ability to prolong progression-free survival, providing patients with a much-needed option for improved disease control. The potential for an effective therapy in this setting may positively impact the overall survival of advanced kidney cancer patients and improve their quality of life.

  1. Advancing the Treatment Landscape:

The success of combining cabozantinib and atezolizumab in the CONTACT-03 trial represents a significant advancement in the treatment of advanced kidney cancer. If approved, this combination therapy will expand treatment options and provide renewed hope for patients who have exhausted previous lines of therapy. It also showcases the potential of combining targeted therapies with immunotherapy to achieve improved outcomes in cancer treatment.


The update on the Phase 3 CONTACT-03 trial evaluating the combination of cabozantinib and atezolizumab in previously treated advanced kidney cancer patients brings exciting news to the field of oncology. The positive results indicate that this treatment approach has the potential to improve progression-free survival for patients in need. If approved, it will contribute to advancing the treatment landscape for advanced kidney cancer and provide a new ray of hope for patients facing this challenging condition. The Exelixis trial exemplifies the continuous efforts to develop innovative therapies that hold promise for groundbreaking advancements in cancer care.